These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 25702351)

  • 1. Metachronous adenocarcinoma of the remnant oesophagus 15 years following multimodal therapy.
    Croghan S; McCormack O; Muldoon C; Ravi N; Reynolds JV
    Ir Med J; 2015 Jan; 108(1):22-3. PubMed ID: 25702351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
    Mulligan ED; Dunne B; Griffin M; Keeling N; Reynolds JV
    Eur J Surg Oncol; 2004 Apr; 30(3):313-7. PubMed ID: 15028315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma.
    Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP
    Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic decisions in patients with operable, non-metastatic oesophageal cancer].
    Fuchs HF; Hölscher AH
    Zentralbl Chir; 2014 Feb; 139(1):32-6. PubMed ID: 24585195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction.
    Zhang X; Watson DI; Jamieson GG; Lally C; Bessell JR; Devitt PG
    ANZ J Surg; 2005 Jul; 75(7):513-9. PubMed ID: 15972033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction.
    Epari K; Cade R
    ANZ J Surg; 2009 Apr; 79(4):251-7. PubMed ID: 19432710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
    Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
    Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
    Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical therapy and chemoradiotherapy for postoperative recurrent esophageal cancer.
    Kubota K; Kuroda J; Yoshida M; Ohta K; Suwa T; Mafune K; Kawase T; Kitahara T; Kubo A; Kitajima M
    Hepatogastroenterology; 2013; 60(128):1961-5. PubMed ID: 24719935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
    Veuillez V; Rougier P; Seitz JF
    Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma.
    Yamamoto S; Ishihara R; Motoori M; Kawaguchi Y; Uedo N; Takeuchi Y; Higashino K; Yano M; Nakamura S; Iishi H
    Am J Gastroenterol; 2011 Jun; 106(6):1048-54. PubMed ID: 21343920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
    Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma.
    Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG
    Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
    McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
    Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagus.
    Bass GA; Furlong H; O'Sullivan KE; Hennessy TP; Walsh TN
    Eur J Cancer; 2014 Apr; 50(6):1065-75. PubMed ID: 24480403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy.
    Stiles BM; Nasar A; Mirza FA; Lee PC; Paul S; Port JL; Altorki NK
    Eur J Cardiothorac Surg; 2012 Oct; 42(4):659-64. PubMed ID: 22491667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?
    Yu E; Dar R; Rodrigues GB; Stitt L; Videtic GM; Truong P; Tomiak A; Ash R; Brecevic E; Inculet R; Malthaner R; Vincent M; Craig I; Kocha W; Lefcoe M
    Radiother Oncol; 2004 Nov; 73(2):141-8. PubMed ID: 15542160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local recurrence after total or subtotal esophagectomy for esophageal cancer.
    Blewett CJ; Miller JD; Ramlawi B; Young JE; BennettWF ; Urschel JD
    J Exp Clin Cancer Res; 2001 Mar; 20(1):17-9. PubMed ID: 11370823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anastomotic recurrence of oesophageal squamous cell carcinoma after transthoracic oesophagectomy.
    Kato H; Tachimori Y; Watanabe H; Yamaguchi H; Ishikawa T; Nakanishi Y; Ochiai A
    Eur J Surg; 1998 Oct; 164(10):759-64. PubMed ID: 9840305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of neoadjuvant chemoradiotherapy on perioperative outcomes, tumor pathology, and survival in clinical stage II and III esophageal cancer.
    Markar SR; Bodnar A; Rosales J; Song G; Low DE
    Ann Surg Oncol; 2013 Nov; 20(12):3935-41. PubMed ID: 23892525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.